Inactive Instrument

Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

Biotechnology & Medical Research

Medical Prognosis Institute A/S : 2016 August, 31 MPI - Interim Report First Half 2016 Read more

August 31, 2016 at 03:48 am EDT

MPI - Interim Report First Half 2016

2016-08-31

Hoersholm; August 31 2016 - Medical Prognosis Institute A/S (MPI) announces the Company's Interim Report First Half 2016.

Interim Report First Half 2016

The Board of Directors for Medical Prognosis Institute A/S has today discussed and approved the Interim Report First Half 2016.

Please find the full Interim report on www.medical-prognosis.com.

For further information, please contact
Peter Buhl Jensen, CEO
e-mail: pbj@medical-prognosis.com
Cell Phone: +45 21 60 89 22

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 31st August 2016.

Certified Advisor: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - Medical Prognosis Institute A/S published this content on 31 August 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 August 2016 07:48:01 UTC.

Original documenthttp://www.medical-prognosis.com/investor-and-media/20160831-mpi-interim-report-first-half-2016/?origin=announcements

Public permalinkhttp://www.publicnow.com/view/423CB71BB1F212F960E35382C1331436A97E5777

Latest news about Medical Prognosis Institute A/S

Top Premarket Gainers	Apr. 15	MT
Top Premarket Gainers	Apr. 12	MT
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split	Apr. 04	MT
Transcript : Allarity Therapeutics, Inc. - Shareholder/Analyst Call	Apr. 01
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	Mar. 27	CI
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding	Mar. 13	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Allarity Therapeutics, Inc. Announces Termination of Marie Foegh as Chief Medical Officer	Mar. 04	CI
Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP	Feb. 12	CI
Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board	Feb. 01	CI
Allarity Therapeutics, Inc. announced that it expects to receive $0.8 million in funding from 3i, LP	Jan. 17	CI
Allarity Therapeutics Announces Executive Changes	Dec. 12	CI
Allarity Therapeutics, Inc. Announces Chief Executive Officer Changes	Dec. 11	CI
Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic	Dec. 05	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Certain Series C Preferred Stock of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Series A Preferred Stock of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Warrants of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Options of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Common Stock of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology	23-09-14	CI
Top Premarket Gainers	23-08-31	MT
Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic for Dovitinib in the Peer-Reviewed Journal PLOS ONE	23-08-30	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Allarity Therapeutics, Inc. Announces Board Changes	23-08-11	CI

Chart Medical Prognosis Institute A/S

Duration

Period

More charts

Company Profile

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs